Cline Scientific AB Series B
Cline Scientific AB (publ), a life science company, develops cancer diagnostics and stem cell therapies in Sweden. The company's clinical-stage projects include StemCART, a stem cell therapy for joint repair; and CellRACE, a cancer diagnostic to predict metastasis. It also develops nanotechnology based products for work within Life Sciences. The company has collaboration with Sahlgrenska that dev… Read more
Cline Scientific AB Series B (CLINE-B) - Net Assets
Latest net assets as of December 2023: Skr20.10 Million SEK
Based on the latest financial reports, Cline Scientific AB Series B (CLINE-B) has net assets worth Skr20.10 Million SEK as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr22.72 Million) and total liabilities (Skr2.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr20.10 Million |
| % of Total Assets | 88.48% |
| Annual Growth Rate | 109.18% |
| 5-Year Change | 696.47% |
| 10-Year Change | 6773.43% |
| Growth Volatility | 1530.59 |
Cline Scientific AB Series B - Net Assets Trend (2012–2023)
This chart illustrates how Cline Scientific AB Series B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cline Scientific AB Series B (2012–2023)
The table below shows the annual net assets of Cline Scientific AB Series B from 2012 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | Skr20.10 Million | +15.14% |
| 2022-12-31 | Skr17.46 Million | +4.31% |
| 2021-12-31 | Skr16.74 Million | +65.42% |
| 2020-12-31 | Skr10.12 Million | +300.90% |
| 2019-12-31 | Skr2.52 Million | -45.38% |
| 2018-12-31 | Skr4.62 Million | +192.51% |
| 2017-12-31 | Skr1.58 Million | -67.85% |
| 2016-12-31 | Skr4.91 Million | -36.58% |
| 2015-12-31 | Skr7.75 Million | +2549.17% |
| 2013-12-31 | Skr292.49K | +4774.80% |
| 2012-12-31 | Skr6.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cline Scientific AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3398721100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr4.50 Million | 22.39% |
| Other Comprehensive Income | Skr17.23 Million | 85.72% |
| Other Components | Skr32.36 Million | 160.95% |
| Total Equity | Skr20.10 Million | 100.00% |
Cline Scientific AB Series B Competitors by Market Cap
The table below lists competitors of Cline Scientific AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Elcora Advanced Materials Corp
PINK:ECORF
|
$188.98K |
|
MURATA MFG
MU:MUR1
|
$188.99K |
|
Great Dane Globale Aktier
CO:GDIGA
|
$189.23K |
|
Great Dane INDEX+
CO:GDIIND
|
$189.29K |
|
TIETO CORPORATION
MU:TTEB
|
$188.84K |
|
Selected Investments Equities
CO:SIIEQT
|
$188.73K |
|
WORLD FUEL SERVICES
BE:WFK
|
$188.69K |
|
Stifel Financial Corporation 5.20% Senior Notes due 2047
NYSE:SFB
|
$188.54K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cline Scientific AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 17,461,186 to 20,103,972, a change of 2,642,786 (15.1%).
- Net loss of 3,147,972 reduced equity.
- New share issuances of 6,177,231 increased equity.
- Other comprehensive income increased equity by 4,200,000.
- Other factors decreased equity by 4,586,473.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-3.15 Million | -15.66% |
| Share Issuances | Skr6.18 Million | +30.73% |
| Other Comprehensive Income | Skr4.20 Million | +20.89% |
| Other Changes | Skr-4.59 Million | -22.81% |
| Total Change | Skr- | 15.14% |
Book Value vs Market Value Analysis
This analysis compares Cline Scientific AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.15x to 0.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.06 | Skr0.07 | x |
| 2013-12-31 | Skr2.92 | Skr0.07 | x |
| 2015-12-31 | Skr1.00 | Skr0.07 | x |
| 2016-12-31 | Skr0.52 | Skr0.07 | x |
| 2017-12-31 | Skr0.17 | Skr0.07 | x |
| 2018-12-31 | Skr0.43 | Skr0.07 | x |
| 2019-12-31 | Skr0.24 | Skr0.07 | x |
| 2020-12-31 | Skr0.53 | Skr0.07 | x |
| 2021-12-31 | Skr0.88 | Skr0.07 | x |
| 2022-12-31 | Skr0.73 | Skr0.07 | x |
| 2023-12-31 | Skr0.67 | Skr0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cline Scientific AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -74.95%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.13x
- Recent ROE (-15.66%) is above the historical average (-657.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -6811.77% | -87.20% | 0.32x | 240.67x | Skr-409.31K |
| 2013 | 97.82% | 125.30% | 0.14x | 5.58x | Skr256.87K |
| 2015 | -29.25% | -553.43% | 0.05x | 1.14x | Skr-3.04 Million |
| 2016 | -57.67% | -310.81% | 0.15x | 1.23x | Skr-3.33 Million |
| 2017 | -211.07% | -729.30% | 0.07x | 3.92x | Skr-3.49 Million |
| 2018 | -54.42% | -306.58% | 0.14x | 1.25x | Skr-2.98 Million |
| 2019 | -95.61% | -853.32% | 0.03x | 3.76x | Skr-2.67 Million |
| 2020 | -20.08% | -1743.07% | 0.01x | 1.10x | Skr-3.04 Million |
| 2021 | -21.33% | -89447.81% | 0.00x | 1.09x | Skr-5.24 Million |
| 2022 | -13.48% | -81.16% | 0.15x | 1.08x | Skr-4.10 Million |
| 2023 | -15.66% | -74.95% | 0.18x | 1.13x | Skr-5.16 Million |
Industry Comparison
This section compares Cline Scientific AB Series B's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cline Scientific AB Series B (CLINE-B) | Skr20.10 Million | -6811.77% | 0.13x | $188.96K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |